ECM
SRPT icon

Element Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Element Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,253
Closed -$430K – 1013
2018
Q2 		$430K Sell
3,253
-399,997
-99% -$37.7M 0.01% 420
2018
Q1 		$29.9M Buy
403,250
+85,020
+27% +$5.67M 0.7% 23
2017
Q4 		$17.7M Buy
+318,230
New +$16.9M 0.36% 79

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Element Capital Management's SRPT Position: Q3 2018 in Review

Element Capital Management sold out of Sarepta Therapeutics (SRPT) in Q3 2018, closing a stake of 3,253 shares — an estimated $430K sold.

Element Capital Management first reported a position in SRPT in Q4 2017 and held it in 3 quarters. The position peaked at $29.9M in Q1 2018. 344 funds tracked by Wall St. Rank hold SRPT as of Q3 2018.

  • Element Capital Management reported no remaining Sarepta Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Element Capital Management sold 3,253 Sarepta Therapeutics shares in Q3 2018, an estimated $430K.
  • Element Capital Management first reported a position in Sarepta Therapeutics in Q4 2017 and held it in 3 quarters.
  • Element Capital Management's Sarepta Therapeutics position peaked at $29.9M in Q1 2018.
  • 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2018.

Based on Element Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.